British pharmaceutical giant AstraZeneca announced a $2.5 billion investment in a research and development center in Beijing, boosting its workforce to 1,700 employees. The partnership with the city’s government includes collaborations with biotech firms and the launch of a joint venture to develop vaccines. CEO Pascal Soriot highlighted the center’s role in global innovation efforts, while news of a potential fine from Chinese authorities led to a 1% drop in AstraZeneca’s shares.
Full Article
GreenTech hails massive sulphides in Whundo core, WA
GreenTech Metals reported promising results from its diamond drill program at the Whundo copper-zinc project near Karratha, achieving significant intercepts such as 7.14m at 1.46% copper and 1.23% zinc from the Austin conductor and 9.94m at 1.32% copper from the Shelby conductor. The drilling program, which faced delays due to weather, aims to explore mineralised extensions along the Whundo trend and assess potential resource expansion, with plans for a second stage focusing on continuity between...
Read more